Just over a month after the FDA accepted Acacia Pharma Ltd.'s US NDA for its novel post-operative nausea and vomiting (PONV) therapy, Baremsis (a low-dose amisulpride injection), and received a PDUFA date of Oct. 5, 2018, the Cambridge, UK-based company announced on Feb. 5 its intention to launch an initial global offering (IGO) on Euronext in Brussels, to raise new funds to support its US marketing preparations.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?